← Back to Clinical Trials
Recruiting NCT07169123

NCT07169123 Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07169123
Status Recruiting
Phase
Sponsor McMaster University
Condition Crohns Disease
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2025-08-18
Primary Completion 2029-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2025-08-18 with a primary completion date of 2029-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study looks at how eating salt affects gut health in people with Crohn's disease. The aim of the study is to find out whether eating more salt increases the breakdown of proteins in the gut and if this makes inflammation and symptoms worse. By studying the link between salt, gut bacteria and inflammation, the study hopes to improve diet advice for people with Crohn's disease. This research may help find specific foods that affect the disease and lead to better, more personalized nutrition plans.

Eligibility Criteria

Inclusion Criteria: * 18 and 70 years of age * Crohn's disease diagnosis * Willing and able to sign written informed consent prior to study entry * Able to comply with the study procedures, in the opinion of the investigator Exclusion Criteria: * Antibiotics, antibacterial agents, or probiotics, currently, or within the last 8 weeks * Alcohol or drug abuse * Pregnancy * Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection

Contact & Investigator

Central Contact

Gaston H Rueda, MD

✉ ruedag@mcmaster.ca

📞 905 521-2100

Principal Investigator

David Armstrong, MD

PRINCIPAL INVESTIGATOR

McMaster University

Frequently Asked Questions

Who can join the NCT07169123 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Crohns Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07169123 currently recruiting?

Yes, NCT07169123 is actively recruiting participants. Contact the research team at ruedag@mcmaster.ca for enrollment information.

Where is the NCT07169123 trial being conducted?

This trial is being conducted at Hamilton, Canada, Hamilton, Canada.

Who is sponsoring the NCT07169123 clinical trial?

NCT07169123 is sponsored by McMaster University. The principal investigator is David Armstrong, MD at McMaster University. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology